A CNS-Directed, AAV9 Gene Therapy Restores Expression and Biochemical Function of Guanidinoacetate Methyltransferase in Models of GAMT Deficiency
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27021035 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Robyn Binsfeld und 7 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Neuroscience Studies, Queen's University, Kingston, ON K7L 3N6, Canada. Hauptthemen laut MEDLINE: Guanidinoacetate N-Methyltransferase, Genetic Therapy, Dependovirus, Movement Disorders. Die Arbeit nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Initiation Grant from Queen’s University.
Abstract (Originalsprache)
Guanidinoacetate methyltransferase (GAMT) is an essential enzyme in the biosynthesis of creatine, an important molecule in energy recycling. GAMT loss of function leads to GAMT deficiency (GAMT-D), an autosomal recessive disorder resulting in low creatine levels and the accumulation of a toxic intermediate, guanidinoacetate (GAA). GAMT-D patients present with intellectual disability and epilepsy, emphasizing the detrimental consequences of disturbed creatine metabolisms in the central nervous system (CNS). Current treatments are not curative and may not restore creatine metabolism in the brain. Here, we present a proof-of concept study testing the first CNS-directed, Adeno-associated virus serotype 9 (AAV9)-based gene therapy for the treatment of GAMT-D. the delivery of GAMT construct to cellular models of GAMT-D effectively restored protein and mRNA expression of GAMT while increasing intracellular creatine content and decreasing GAA accumulation. In murine models of GAMT-D, treatment with scAAV9.hGAMT, delivered intrathecally, resulted in increased creatine content as well as significant decreases in GAA accumulation in the CNS and peripheral organs. Overall, we found that scAAV9.hGAMT represents a promising gene therapy for treating GAMT-D, warranting further investigation in animal models to determine an appropriate therapeutic window for both efficacy and safety that allows for translation into human patients in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Neuroscience Studies, Queen's University, Kingston, ON K7L 3N6, Canada.
- The Hospital for Sick Children, Toronto, ON M5G 1E8, Canada.
- Peter Gilgan Center for Research and Learning, Toronto, ON M5G 0A4, Canada.
- Department of Pediatrics, Queen's University, Kingston, ON K7L 3N6, Canada.
- Departments of Pediatrics and Biochemistry, University of Toronto, Toronto, ON M5S 1A1, Canada.
ORCID-Profile: Robyn Binsfeld, Melissa Mitchell, Tesla Peretti, Andreas Schulze, Jagdeep S Walia
Förderung
- Research Initiation Grant from Queen’s University
Zitieren
APA
Binsfeld, R., Webster, T., Tkachyova, I., Tropak, M., Mitchell, M., Peretti, T., Schulze, A., & Walia, J. S. (2026). A CNS-Directed, AAV9 Gene Therapy Restores Expression and Biochemical Function of Guanidinoacetate Methyltransferase in Models of GAMT Deficiency. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27021035
Vancouver
Binsfeld R, Webster T, Tkachyova I, Tropak M, Mitchell M, Peretti T, et al. A CNS-Directed, AAV9 Gene Therapy Restores Expression and Biochemical Function of Guanidinoacetate Methyltransferase in Models of GAMT Deficiency. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27021035
BibTeX
@article{Binsfeld2026,
author = {Binsfeld, Robyn and Webster, Troy and Tkachyova, Ilona and Tropak, Michael and Mitchell, Melissa and Peretti, Tesla and Schulze, Andreas and Walia, Jagdeep S},
title = {A CNS-Directed, AAV9 Gene Therapy Restores Expression and Biochemical Function of Guanidinoacetate Methyltransferase in Models of GAMT Deficiency},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27021035}
}
EUVIMED